Philip A. Watson

8.0k total citations · 3 hit papers
25 papers, 4.3k citations indexed

About

Philip A. Watson is a scholar working on Pulmonary and Respiratory Medicine, Molecular Biology and Genetics. According to data from OpenAlex, Philip A. Watson has authored 25 papers receiving a total of 4.3k indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Pulmonary and Respiratory Medicine, 8 papers in Molecular Biology and 7 papers in Genetics. Recurrent topics in Philip A. Watson's work include Prostate Cancer Treatment and Research (14 papers), Estrogen and related hormone effects (7 papers) and Radiopharmaceutical Chemistry and Applications (3 papers). Philip A. Watson is often cited by papers focused on Prostate Cancer Treatment and Research (14 papers), Estrogen and related hormone effects (7 papers) and Radiopharmaceutical Chemistry and Applications (3 papers). Philip A. Watson collaborates with scholars based in United States, Canada and Sweden. Philip A. Watson's co-authors include Charles L. Sawyers, Vivek Arora, John Wongvipat, Yu Chen, Minna Balbas, Howard I. Scher, Chris Tran, Derek S. Welsbie, Tomasz M. Beer and Celestia S. Higano and has published in prestigious journals such as Nature, Science and Proceedings of the National Academy of Sciences.

In The Last Decade

Philip A. Watson

24 papers receiving 4.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer

2009 1.7k citations Chris Tran, Samedy Ouk et al. Science profile →
Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer

2015 1.0k citations Philip A. Watson, Vivek Arora et al. Nature reviews. Cancer profile →
Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor

2010 497 citations Philip A. Watson, John Wongvipat et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Philip A. Watson United States	17	3.1k	1.8k	1.2k	901	805	25	4.3k
Vivek Arora United States	21	3.3k 1.1×	2.0k 1.1×	1.3k 1.1×	931 1.0×	803 1.0×	38	4.8k
Scott M. Dehm United States	37	3.7k 1.2×	2.7k 1.5×	1.5k 1.2×	799 0.9×	1.1k 1.4×	116	5.2k
Nora M. Navone United States	42	2.3k 0.7×	2.8k 1.5×	1.2k 1.0×	1.8k 2.0×	382 0.5×	136	5.4k
Michael C. Haffner United States	34	2.5k 0.8×	2.8k 1.5×	1.5k 1.3×	1.2k 1.3×	310 0.4×	120	5.3k
John Wongvipat United States	23	5.1k 1.7×	3.3k 1.8×	2.0k 1.6×	1.6k 1.8×	1.1k 1.3×	35	7.4k
Ricardo M. Attar United States	30	827 0.3×	1.7k 0.9×	652 0.5×	877 1.0×	864 1.1×	72	3.2k
Robert A. Sikes United States	31	1.3k 0.4×	1.6k 0.9×	608 0.5×	956 1.1×	299 0.4×	71	3.3k
M. E. Harper United Kingdom	28	1.6k 0.5×	1.7k 0.9×	570 0.5×	1.9k 2.1×	668 0.8×	66	4.2k
Angelo Raffaele Bianco Italy	34	987 0.3×	1.4k 0.8×	860 0.7×	2.6k 2.9×	324 0.4×	100	4.2k
Jacek Pinski United States	31	1.1k 0.4×	1.1k 0.6×	415 0.3×	727 0.8×	247 0.3×	114	2.9k

Countries citing papers authored by Philip A. Watson

Since Specialization

Citations

This map shows the geographic impact of Philip A. Watson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Philip A. Watson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Philip A. Watson more than expected).

Fields of papers citing papers by Philip A. Watson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Philip A. Watson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Philip A. Watson. The network helps show where Philip A. Watson may publish in the future.

Co-authorship network of co-authors of Philip A. Watson

This figure shows the co-authorship network connecting the top 25 collaborators of Philip A. Watson. A scholar is included among the top collaborators of Philip A. Watson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Philip A. Watson. Philip A. Watson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Wasmuth, Elizabeth V., Arnaud Vanden Broeck, Kayla E. Lawrence, et al.. (2022). Allosteric interactions prime androgen receptor dimerization and activation. Molecular Cell. 82(11). 2021–2031.e5. 32 indexed citations

Lee, Eugine, John Wongvipat, Danielle Choi, et al.. (2019). GREB1 amplifies androgen receptor output in human prostate cancer and contributes to antiandrogen resistance. eLife. 8. 16 indexed citations

Adams, Elizabeth, Wouter R. Karthaus, Elizabeth Hoover, et al.. (2019). FOXA1 mutations alter pioneering activity, differentiation and prostate cancer phenotypes. Nature. 571(7765). 408–412. 168 indexed citations

Zhang, Zeda, Wouter R. Karthaus, José Maurício Mota, et al.. (2019). Abstract 111: Tumor microenvironment derived NRG1 promotes antiandrogen resistance in prostate cancer. Tumor Biology. 111–111.

Kim, Kwanghee, Philip A. Watson, Souhil Lebdai, et al.. (2018). Androgen Deprivation Therapy Potentiates the Efficacy of Vascular Targeted Photodynamic Therapy of Prostate Cancer Xenografts. Clinical Cancer Research. 24(10). 2408–2416. 17 indexed citations

Thorek, Daniel L.J., Anson T. Ku, Nicholas Mitsiades, et al.. (2018). Harnessing Androgen Receptor Pathway Activation for Targeted Alpha Particle Radioimmunotherapy of Breast Cancer. Clinical Cancer Research. 25(2). 881–891. 21 indexed citations

McDevitt, Michael R., Daniel L.J. Thorek, Takeshi Hashimoto, et al.. (2018). Feed-forward alpha particle radiotherapy ablates androgen receptor-addicted prostate cancer. Nature Communications. 9(1). 39 indexed citations

Watson, Philip A., Vivek Arora, & Charles L. Sawyers. (2015). Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer. Nature reviews. Cancer. 15(12). 701–711. 1015 indexed citations breakdown →

Doran, Michael G., Philip A. Watson, Sarah M. Cheal, et al.. (2014). Annotating STEAP1 Regulation in Prostate Cancer with ⁸⁹Zr Immuno-PET. Journal of Nuclear Medicine. 55(12). 2045–2049. 20 indexed citations

10.

Daskalogiannakis, John, et al.. (2010). Force characteristics of nickel-titanium open-coil springs. American Journal of Orthodontics and Dentofacial Orthopedics. 138(2). 142.e1–142.e7. 6 indexed citations

11.

Daskalogiannakis, John, et al.. (2010). Editor's Comment and Q&A. American Journal of Orthodontics and Dentofacial Orthopedics. 138(2). 142–143. 1 indexed citations

12.

Tran, Chris, Samedy Ouk, Nicola J. Clegg, et al.. (2009). Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer. Science. 324(5928). 787–790. 1689 indexed citations breakdown →

13.

Kim, Kwanghee, et al.. (2008). Epidermal Growth Factor Receptor vIII Expression in U87 Glioblastoma Cells Alters Their Proteasome Composition, Function, and Response to Irradiation. Molecular Cancer Research. 6(3). 426–434. 23 indexed citations

14.

Jiao, Jing, Shunyou Wang, Rong Qiao, et al.. (2007). Murine Cell Lines Derived from Pten Null Prostate Cancer Show the Critical Role of PTEN in Hormone Refractory Prostate Cancer Development. Cancer Research. 67(13). 6083–6091. 128 indexed citations

15.

Gorokhovsky, V., et al.. (2005). The effect of multilayer filtered arc coatings on mechanical properties, corrosion resistance and performance of periodontal dental instruments. Surface and Coatings Technology. 200(18-19). 5614–5630. 12 indexed citations

16.

Watson, Philip A., Kwanghee Kim, Kai-Shun Chen, & Michael N. Gould. (2002). Androgen-dependent mammary carcinogenesis in rats transgenic for the Neu proto-oncogene. Cancer Cell. 2(1). 67–79. 16 indexed citations

17.

Watson, Philip A., et al.. (2002). Biomimetic dental implants--new ways to enhance osseointegration.. PubMed. 68(5). 286–8. 34 indexed citations

18.

Schwarze, Steven R., Yan Shi, Vivian Fu, Philip A. Watson, & David F. Jarrard. (2001). Role of cyclin-dependent kinase inhibitors in the growth arrest at senescence in human prostate epithelial and uroepithelial cells. Oncogene. 20(57). 8184–8192. 82 indexed citations

19.

Watson, Philip A. & Paul Snell. (1996). AIDS in Cote d'lvoire - Ten Years On. Journal of Public Health. 18(1). 107–111. 3 indexed citations

20.

Lee, Gareth, et al.. (1994). The simulation of New Street station. OR Insight. 7(4). 27–31. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact